Full-Time

Itepekimab Global Health Economics and Value Assessment Business Partner

Director

Confirmed live in the last 24 hours

Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and life-saving vaccines

Biotechnology
Healthcare

Senior

Cambridge, MA, USA

Onsite presence required.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • 5 years of experience in health economics, outcomes research, or a related field.
  • Advanced degree (PhD, MD, MS, MPH, or PharmD) in a scientific discipline.
  • English fluent, both written and oral.
  • Strong communication skills, both verbal and written, including presentation skills. Significant experience making presentations to senior management is preferred.
  • Strong ability to partner with HEVA colleagues and other (i.e. non-HEOR) functional areas.
  • Demonstrated experience in applying various HEOR methods. Understanding the principles of evidence-based medicine and clinical research.
  • Knowledge of global HTA processes and guidelines; experience with HTA submissions preferred.
  • Understanding of the legal and regulatory environment of the pharmaceutical industry, demonstrated integrity on work-related compliance considerations and solid ethics.
Responsibilities
  • This role will be responsible for the design and execution of Health Economic and Outcomes Research (HEOR) research in the forms of economic modeling, database analysis, observational research, Clinical Outcomes Assessment (COA) development and validation, systematic literature review, evidence synthesis, value dossier development and other types of HEOR.
  • This role will set the HEOR evidence generation priorities for Itepekimab indications under development and incorporate them into broader Sanofi planning documents such as the integrated evidence generation plan (IEGP).
  • This role will operate as part of a multi-functional global development team that is responsible for designing clinical research programs to meet the evidentiary standards of regulators, HTA organizations, reimbursement authorities, third-party payers and other organizations that review evidence relevant to Sanofi medicines.

Sanofi provides healthcare solutions through its pharmaceutical and biotechnology products, focusing on treatments and vaccines for various medical needs. The company conducts extensive research and development to create new therapies and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi's products include prescription medicines, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and strategic partnerships, allowing it to maintain a diverse pipeline of products. The company's goal is to enhance health outcomes and improve the quality of life for people globally.

Company Stage

IPO

Total Funding

$2B

Headquarters

Paris, France

Founded

1973

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's AI tool Muse accelerates patient recruitment in clinical trials.
  • Dupixent's EU approval expands Sanofi's pediatric treatment market.
  • BrightInsight partnership enhances digital health solutions for better patient outcomes.

What critics are saying

  • Increased competition in the rare disease sector from biotech startups.
  • Regulatory risks due to liver enzyme elevations in tolebrutinib trials.
  • Dependence on strategic partnerships like BrightInsight for digital health initiatives.

What makes Sanofi unique

  • Sanofi's Care4Rare program supports innovative solutions for rare diseases.
  • The MyWay app enhances patient engagement and medication adherence.
  • Tolebrutinib is the first brain-penetrant BTK inhibitor for multiple sclerosis.

Help us improve and share your feedback! Did you find this helpful?